featured
Ribociclib Plus Letrozole in Male Patients With HR+/HER2− Advanced Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Breast Cancer Research and Treatment
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial
Breast Cancer Res Treat 2022 Feb 25;[EPub Ahead of Print], M Campone, M De Laurentiis, C Zamagni, I Kudryavcev, M Agterof, U Brown-Glaberman, M Palácová, S Chatterjee, L Menon-Singh, J Wu, M MartínFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.